To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

December 3, 2023

We URGENTLY Need Your Support In Reaching Out To Your Senators & Representatives!

There have been few actionable cancer bills that have the potential to have as much impact as the Promising Pathway Act (PPA), especially for those facing a devastating brain cancer diagnosis. The Promising Pathway Act, reintroduced in Congress on June 8, 2023, will double the speed of revolutionary treatments and could lead to uncovering the cure we've been seeking for over a century.

As Congress continues to consider legislative solutions to support patients with rare and life-threatening diseases, and in light of the current congressional efforts to reauthorize the FDA user fee program, we urge them to support and pass the Promising Pathway Act. The Promising Pathway Act is a way to advance trials and protect patients, and may also be the most effective way to save lives. It is for this reason that over 50 foundations and chapters in 21 states and 3 countries support this measure. 

The Promising Pathway Act provides the framework to protect patient safety, while also providing patients with the opportunity to access potentially life-saving treatments the current system prevents them from accessing. Under the current compassionate access system, once the treatment is approved, there exists no centralized, third-party tracking system on patient responses or side effects. This is both reckless and short-sighted. Through the Promising Pathway Act, third-party registries are required both for communication to the patient population and researchers, but also to eventually assist in the full drug approval determination. This is also critical in the design of combinational therapy options as it will demonstrate future considerations of care. The FDA approval pathways must be continually rethought and redesigned to balance faster access to therapies with increased post-market surveillance requirements.


Sponsor logos


Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
corporate partners
upcoming events
About us
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram